Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

In 2018, a case report studied the effects of Tofacitinib, a selective Janus Kinase inhibitor 1 and 3, on six patients with alopecia areata and alopecia universalis. All patients showed significant hair regrowth after treatment, with effects noticeable by the end of 12 weeks. Four patients continued treatment and were under follow-up, with one not relapsing after stopping the drug for 4 months, and another developing alopecia areata patches in the eyebrows within 2 months of stopping Tofacitinib. Two patients experienced acneiform eruptions, managed with topicals. The report concluded that Tofacitinib effectively treated alopecia without significant adverse side effects, but recommended further controlled studies to confirm its safety and efficacy.